Archive for the ‘eFFECTOR’ Category

Effector Therapeutics

January 8th, 2016 | Posted in 2015, eFFECTOR

San Diego’s Effector Therapeutics a raised $40 million in venture financing, putting the biotech on track to enter the clinic with a Phase 1/2 study of its lead cancer drug called eFT508.

eFFECTOR Therapeutics

August 7th, 2015 | Posted in 2015, eFFECTOR

Daide Ruggero, of San Diego-based eFFECTOR Therapeutics, published what is considered groundbreaking research in the pre-eminent biomedical journal Cell demonstrating preclinical promise for a cancer treatment approach that’s centered on selectively regulating the cell’s protein synthesis process, known as translation.